Clinical Trial Update: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial to assess the safety of HDP-101 in patients with relapsed or refractory multiple myeloma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Disorder

Drugs mentioned

• HDP-101

Snippet

Sponsor: Heidelberg Pharma AG | Conditions: Multiple Myeloma, Plasma Cell Disorder | Phase 1, Phase 2 | Status: RECRUITING